EUVIMEDEUVIMED entdecken
Open Access

Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program

Julia Cave Arbanas, Cheryl L Damberg, Mei Leng, Nina Harawa, Catherine A Sarkisian, Bruce E Landon, John N Mafi

JAMA Internal Medicine · 01.08.2023 · 183 (8) · 885

DOI: 10.1001/jamainternmed.2023.1749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.08.2023. Verfasst von Julia Cave Arbanas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles. Hauptthemen laut MEDLINE: Medicare, Health Expenditures. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS, NIA NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This cross-sectional cost analysis uses data from the 2018 Health and Retirement Study to estimate the potential future Medicare spending and beneficiary costs for lecanemab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicareHealth ExpendituresHumansAgedUnited StatesCosts and Cost AnalysisAntibodies, Monoclonal, Humanized

Substanzen

lecanemabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
  • RAND Corporation, Santa Monica, California.
  • Fielding School of Public Health at University of California, Los Angeles.
  • VA Greater Los Angeles Healthcare System Geriatrics Research & Clinical Center (GRECC), Los Angeles, California.
  • Harvard Medical School and the Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Förderung

  • NCRR NIH HHS
  • NIA NIH HHS
  • NIMH NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Arbanas, J. C., Damberg, C. L., Leng, M., Harawa, N., Sarkisian, C. A., Landon, B. E., & Mafi, J. N. (2023). Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program. JAMA Internal Medicine, 183(8), 885. https://doi.org/10.1001/jamainternmed.2023.1749

Vancouver

Arbanas JC, Damberg CL, Leng M, Harawa N, Sarkisian CA, Landon BE, et al. Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program. JAMA Internal Medicine. 2023;183(8):885. doi:10.1001/jamainternmed.2023.1749

BibTeX
@article{Arbanas2023,
  author = {Arbanas, Julia Cave and Damberg, Cheryl L and Leng, Mei and Harawa, Nina and Sarkisian, Catherine A and Landon, Bruce E and Mafi, John N},
  title = {Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program},
  journal = {JAMA Internal Medicine},
  year = {2023},
  volume = {183},
  number = {8},
  pages = {885},
  doi = {10.1001/jamainternmed.2023.1749}
}
Kostenlos starten →